Endocrine Therapy Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Real-world clinical evaluation of natural and induced vasomotor symptoms in the USA and Europe
CONCLUSION: Significant burden from the triad of natural or induced menopausal symptoms, sleep disturbances and mood changes affected women's daily activities, work and quality of life more than vasomotor symptoms alone.PMID:38695491 | DOI:10.1080/13697137.2024.2340472 (Source: Climacteric)
Source: Climacteric - May 2, 2024 Category: Geriatrics Authors: Sheryl Kingsberg Victoria Banks Cecilia Caetano Cecile Janssenswillen Carsten Moeller Nils Schoof Lauren Lee Megan Scott Rossella E Nappi Source Type: research

Sesamolin serves as an MYH14 inhibitor to sensitize endometrial cancer to chemotherapy and endocrine therapy via suppressing MYH9/GSK3 β/β-catenin signaling
CONCLUSIONS: Herein, we identified that EC prognosis-associated MYH14 was independently responsible for poor overall survival time of patients, and it augmented EC progression by activating Wnt/β-catenin signaling. Targeting MYH14 by sesamolin, a cytotoxicity-based approach, can be applied synergistically with chemotherapy and endocrine therapy to eventually mitigate EC development. This study emphasizes MYH14 as a potential target and sesamolin as a valuable natural drug for EC therapy.PMID:38698330 | PMC:PMC11067147 | DOI:10.1186/s11658-024-00583-9 (Source: Cellular and Molecular Biology Letters)
Source: Cellular and Molecular Biology Letters - May 2, 2024 Category: Biochemistry Authors: Yibin Lin Xiao Chen Linping Lin Benhua Xu Xiaofeng Zhu Xian Lin Source Type: research

H3K27ac-induced RHOXF2 activates Wnt2/ β-catenin pathway by binding to HOXC13 to aggravate the malignant progression of triple negative breast cancer
In conclusion, RHOXF2 activated by H3K27ac functioned as a tumor promoter in TNBC via mediating Wnt2/β-catenin pathway by binding to HOXC13, which provided promising insight into exploration on TNBC therapy.PMID:38697448 | DOI:10.1016/j.cellsig.2024.111196 (Source: Cellular Signalling)
Source: Cellular Signalling - May 2, 2024 Category: Cytology Authors: Man Guo Ruoyan Wang Mandi Nie Hao Zhang Cao Wang Chunfeng Song Shurun Niu Source Type: research

GSE266407 ESR1 fusions invoke breast cancer subtype-dependent enrichment of ligand independent oncogenic signatures and phenotypes [ChIP-seq]
Contributors : Megan E Yates ; Zheqi Li ; Yiting Li ; Hannah Guzolik ; Xiaosong Wang ; Tiantong Liu ; Jagmohan Hooda ; Jennifer M Atkinson ; Adrian V Lee ; Steffi OesterreichSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensBreast cancer is a leading cause of female mortality and despite advancements in personalized therapeutics, metastatic disease largely remains incurable due to drug resistance. The estrogen receptor (ER, ESR1) is expressed in two-thirds of all breast cancer, and under endocrine stress, somatic ESR1 mutations arise in ~30% of cases that result in ...
Source: GEO: Gene Expression Omnibus - May 2, 2024 Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Homo sapiens Source Type: research

Fertility Preservation in Patients with Breast Cancer
AbstractPurpose of ReviewMany breast cancer treatments are gonadotoxic, which can result in infertility in survivors. Patients should be counseled on the impact of cancer treatment on future fertility and their options regarding fertility preservation. The main purpose of this narrative review is to discuss the implications of breast cancer treatment on future fertility and review various strategies for fertility preservation and their safety in this population.Recent FindingsThere is no demonstrated effect of ovarian stimulation, GnRH agonist therapy, or ovarian tissue cryopreservation/transplantation on breast cancer out...
Source: Current Breast Cancer Reports - May 2, 2024 Category: Cancer & Oncology Source Type: research

Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
Conclusion: In the PHERGain trial, an increased SUVmax cutoff (≥77%) after 2 cycles of exclusive HP (with or without endocrine therapy) achieves a pCR in the range of the control arm with chemotherapy plus HP (59.5% vs. 57.7%, respectively), further identifying a subgroup of patients with HER2-addicted tumors. However, the original cutoff (≥40%) maximizes the number of patients who could avoid chemotherapy. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - May 1, 2024 Category: Nuclear Medicine Authors: Gebhart, G., Keyaerts, M., Guiot, T., Flamen, P., Ruiz-Borrego, M., Stradella, A., Bermejo, B., Escriva-de-Romani, S., Calvo Martinez, L., Ribelles, N., Fernandez-Abad, M., Albacar, C., Colleoni, M., Garrigos, L., Atienza de Frutos, M., Dalenc, F., Prat, Tags: Clinical Investigations Source Type: research

Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery?
ConclusionThis review found that one out of three patients becomes eligible for BCS after treatment with NET. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 1, 2024 Category: Cancer & Oncology Source Type: research

Erratum: Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
J Clin Oncol. 2024 Apr 30:JCO2400711. doi: 10.1200/JCO.24.00711. Online ahead of print.NO ABSTRACTPMID:38687953 | DOI:10.1200/JCO.24.00711 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 30, 2024 Category: Cancer & Oncology Source Type: research

Erratum: Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
J Clin Oncol. 2024 Apr 30:JCO2400711. doi: 10.1200/JCO.24.00711. Online ahead of print.NO ABSTRACTPMID:38687953 | DOI:10.1200/JCO.24.00711 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 30, 2024 Category: Cancer & Oncology Source Type: research

Cancers, Vol. 16, Pages 1749: Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy
Witkiewicz The largest portion of breast cancer patients diagnosed after 70 years of age present with hormone receptor-positive (HR+) breast cancer subtypes. Cyclin-dependent kinase (CDK) 4/6 inhibitor treatment, in conjunction with endocrine therapy, has become standard-of-care for metastatic HR+ breast cancer. In total, 320 patients with metastatic breast cancer receiving CDK4/6 inhibitor combined with fulvestrant or an aromatase inhibitor were enrolled in an ongoing observational study or were included in an IRB-approved retrospective study. All patients receiving CDK4/6 inhibitor-based therapy that were &g...
Source: Cancers - April 30, 2024 Category: Cancer & Oncology Authors: Thomas N. O ’Connor Emily Schultz Jianxin Wang Tracey O ’Connor Ellis Levine Erik S. Knudsen Agnieszka K. Witkiewicz Tags: Article Source Type: research